Protagenic Therapeutics, Inc. (PTIX) 10-Year Financial Performance & Capital Metrics

PTIX • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersPsychiatric & CNS Disorders

AboutProtagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.Show more

Revenue $0
EBITDA -$6M -25.6%
Net Income -$6M -10.5%
EPS (Diluted) -1.13 +1.7%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -236.05% -149.9%
ROIC -549.97% -663.5%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Weak momentum: RS Rating 1 (bottom 1%)
✗Shares diluted 12.8% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-57.95%

EPS CAGR

10Y-

5Y-

3Y-

TTM23.58%

ROCE

10Y Avg-484.89%

5Y Avg-317.7%

3Y Avg-123.51%

Latest-243.57%

Peer Comparison

Psychiatric & CNS Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
ACADACADIA Pharmaceuticals Inc.	4.48B	26.46	19.46	31.85%	24.94%	28.47%	3.51%	0.07
JAZZJazz Pharmaceuticals plc	9.87B	162.43	18.78	6.12%	-8.86%	-9.31%	13.66%	1.51
CPRXCatalyst Pharmaceuticals, Inc.	2.75B	22.35	17.06	23.49%	37.63%	23.64%	8.71%	0.00
HRMYHarmony Biosciences Holdings, Inc.	2.06B	35.76	14.25	22.8%	22.48%	22.23%	10.62%	0.28
ALKSAlkermes plc	4.81B	29.15	13.43	-6.36%	22.27%	19.55%	8.43%	0.05
PRTCPureTech Health plc	437.45M	18.10	9.05	44.98%	-495.91%	-8.53%		0.05
LBRXLB Pharmaceuticals Inc Common Stock	500.67M	19.79	-1.11
NMRANeumora Therapeutics, Inc. Common Stock	363.67M	2.14	-1.40			-178.79%		0.01

Profit & Loss

	Jun 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	534	148	347	339	286	0	30	28.22K	50.29K
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	0	-534	-148	-347	-339	-286	0	-30	-28.22K	-50.29K
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	0.72%	-1.34%	0.02%	0.16%	1%	-	-939.6%	-0.78%
Operating Expenses+	491K	1.83M	2.37M	2.31M	2.09M	2.55M	4.14M	3.56M	4.5M	5.7M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	491K	1.3M	1.65M	1.43M	1.28M	1.85M	3M	1.97M	1.18M	1.76M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	464	417.87K	717.45K	881.19K	807.95K	699.8K	1.14M	1.59M	3.32M	3.85M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	404.17K	0	0	53	203	-1K	0	0	97K
Operating Income+	-491K	-2.23M	-2.37M	-2.31M	-2.09M	-2.55M	-4.14M	-3.56M	-4.53M	-5.7M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	0.5%	-3.55%	-0.06%	0.02%	0.1%	-0.22%	-0.62%	0.14%	-0.27%	-0.26%
EBITDA+	-490.86K	-2.23M	-2.36M	-2.31M	-2.09M	-2.55M	-4.14M	-3.56M	-4.5M	-5.65M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-0.41%	-3.55%	-0.06%	0.02%	0.1%	-0.22%	-0.62%	0.14%	-0.26%	-0.26%
D&A (Non-Cash Add-back)	143	534	148	347	339	286	286	30	28.22K	50.29K
EBIT	-1.02M	-2.27M	-2.37M	-2.31M	-2.09M	-2.55M	-4.14M	-3.42M	-4.53M	-5.53M
Net Interest Income+	0	-6.25K	0	0	-13.07K	-246K	-464K	48.33K	156.79K	43.46K
Interest Income	0	907	13.89K	2.79K	2.81K	502	33.21K	185.79K	264.48K	43.47K
Interest Expense	18K	7.16K	13.89K	2.79K	15.89K	246.18K	496.91K	137.46K	107.68K	0
Other Income/Expense	1.62K	-42.33K	105.69K	-243K	335.22K	2.88K	-383K	2.28K	-474K	175.61K
Pretax Income+	-1.02M	-2.28M	-2.26M	-2.56M	-1.75M	-2.55M	-4.52M	-3.56M	-5M	-5.53M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	-33K	0	0	0	15.89K	0	0	0	0	0
Effective Tax Rate %	0.47%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-476K	-2.28M	-2.26M	-2.56M	-1.75M	-2.55M	-4.52M	-3.56M	-5M	-5.53M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	0.56%	-3.78%	0.01%	-0.13%	0.32%	-0.46%	-0.77%	0.21%	-0.41%	-0.1%
Net Income (Continuing)	-1.02M	-2.28M	-2.26M	-2.56M	0	-2.55M	-4.52M	-3.56M	-5M	-5.53M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	-74K	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-73.23	-1.72	-0.88	-1.00	-0.69	-1.00	-1.24	-0.82	-1.15	-1.13
EPS Growth %	0.56%	0.98%	0.49%	-0.14%	0.31%	-0.45%	-0.24%	0.34%	-0.4%	0.02%
EPS (Basic)	-73.23	-1.72	-0.88	-1.00	-0.69	-1.00	-1.24	-0.82	-1.15	-1.13
Diluted Shares Outstanding	118.09K	1.33M	2.56M	2.56M	2.56M	2.58M	3.69M	4.32M	4.34M	4.9M
Basic Shares Outstanding	118K	1.33M	2.56M	2.56M	2.56M	2.58M	3.69M	4.32M	4.34M	4.9M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Jun 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	132K	3.16M	1.78M	696.27K	841.98K	879.25K	11.06M	8.04M	4.2M	1.88M
Cash & Short-Term Investments	62K	3.1M	1.69M	612.87K	798.62K	671.09K	10.37M	7.98M	4.06M	1.84M
Cash Only	62K	3.1M	399.69K	362.49K	798.62K	671.09K	541.17K	215.19K	1.29M	1.84M
Short-Term Investments	0	0	1.29M	250.39K	0	0	9.83M	7.76M	2.77M	0
Accounts Receivable	0	0	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	0	0	0	0	0
Total Non-Current Assets+	1K	1.1K	1.02K	611	296	0	0	1.77K	123.33K	73.05K
Property, Plant & Equipment	1K	1.1K	1.02K	611	296	0	0	1.77K	123.33K	73.05K
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	0	0	0	0	0	0	0
Total Assets+	133K	3.16M	1.78M	696.88K	842.27K	879.25K	11.06M	8.04M	4.32M	1.96M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	-0.46%	22.77%	-0.44%	-0.61%	0.21%	0.04%	11.58%	-0.27%	-0.46%	-0.55%
Total Current Liabilities+	189K	684.86K	561.69K	907.77K	1.2M	655.19K	799.53K	1.12M	655.25K	942.76K
Accounts Payable	168K	13.4K	10.96K	10.05K	163.03K	141.86K	278.96K	155.49K	113.8K	102.96K
Days Payables Outstanding	-	9.16K	27.04K	10.57K	175.53K	181.05K	-	1000K	1.47K	747.35
Short-Term Debt	0	0	0	0	0	0	0	344.23K	0	0
Deferred Revenue (Current)	-399	0	0	0	0	0	0	0	0	0
Other Current Liabilities	0	516.87K	425.84K	676.08K	332.22K	83.67K	0	0	0	0
Current Ratio	0.70x	4.62x	3.17x	0.77x	0.70x	1.34x	13.83x	7.18x	6.41x	2.00x
Quick Ratio	0.70x	4.62x	3.17x	0.77x	0.70x	1.34x	13.83x	7.18x	6.41x	2.00x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	515K	0	0	52.37K	279.37K	1.37M	318.43K	0	0	0
Long-Term Debt	515K	0	0	0	279.37K	1.37M	318.43K	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	0
Total Liabilities	704K	684.86K	561.69K	907.77K	1.48M	2.03M	1.12M	1.12M	655.25K	942.76K
Total Debt+	515K	0	0	0	279.37K	1.37M	318.43K	344.23K	0	0
Net Debt	453K	-3.1M	-399.69K	-362.49K	-519.25K	702.71K	-222.74K	129.04K	-1.29M	-1.84M
Debt / Equity	-	-	-	-	-	-	0.03x	0.05x	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-27.28x	-311.92x	-170.27x	-829.39x	-131.31x	-10.37x	-8.33x	-25.88x	-42.04x	-
Total Equity+	-571K	2.48M	1.22M	-210.88K	-634.37K	-1.15M	9.94M	6.92M	3.67M	1.01M
Equity Growth %	-7.16%	5.34%	-0.51%	-1.17%	-2.01%	-0.81%	9.65%	-0.3%	-0.47%	-0.72%
Book Value per Share	-4.84	1.87	0.48	-0.08	-0.25	-0.44	2.70	1.60	0.84	0.21
Total Shareholders' Equity	-497K	2.48M	1.22M	-210.88K	-634.37K	-1.15M	9.94M	6.92M	3.67M	1.01M
Common Stock	1	1.03K	1.03K	1.03K	1.03K	1.04K	1.72K	434	444	725
Retained Earnings	-1.55M	-8.58M	-10.84M	-13.4M	-15.15M	-17.7M	-22.22M	-25.78M	-30.78M	-36.3M
Treasury Stock	-100K	0	0	0	0	0	0	0	0	0
Accumulated OCI	-149	-181.63K	-167.81K	-170.54K	-172.36K	-171.59K	-248.35K	-676.91K	-113.55K	-129.85K
Minority Interest	-74K	0	0	0	0	0	0	0	0	0

Cash Flow

	Jun 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-378K	-1.14M	-1.38M	-1.07M	-487.99K	-1.35M	-2.8M	-1.99M	-3.7M	-4.22M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	0.52%	-2.02%	-0.21%	0.22%	0.54%	-1.76%	-1.07%	0.29%	-0.86%	-0.14%
Net Income	-476K	-2.28M	-2.26M	-2.56M	-1.75M	-2.55M	-4.52M	-3.56M	-5M	-5.53M
Depreciation & Amortization	1K	534	148	347	339	286	427.14K	30	28.22K	50.29K
Stock-Based Compensation	479	546.13K	888.28K	1.13M	797.76K	1.65M	1.52M	864.68K	666.83K	923.14K
Deferred Taxes	0	440.78K	-91.8K	0	-348.29K	-248.55K	-427.14K	0	0	0
Other Non-Cash Items	-7K	150K	99.78K	246.19K	110.91K	154.9K	345.95K	156.85K	716.09K	-132.14K
Working Capital Changes	104K	-1.94K	-16.87K	109.73K	702.2K	-361.43K	-140.39K	540.13K	-114.41K	467.54K
Change in Receivables	0	6	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	30K	52.25K	17.26K	98.59K	99.54K	0	340.12K	-91.6K	-27.33K	0
Cash from Investing+	-1K	0	-1.29M	1.05M	250K	0	-9.91M	1.6M	4.78M	2.8M
Capital Expenditures	-1K	0	0	0	0	0	0	-1.8K	-149.78K	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	-1.29K	1.05K	0	0	0	-46.05K	0	51.73K
Cash from Financing+	340K	4.28M	0	0	670K	1.22M	12.58M	0	0	1.96M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	4.26M	0	0	0	-104.09K	869.63K	0	0	-454
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-379K	-1.14M	-1.38M	-1.07M	-487.99K	-1.35M	-2.8M	-2M	-3.85M	-4.22M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	0.52%	-2.01%	-0.21%	0.22%	0.54%	-1.76%	-1.07%	0.29%	-0.93%	-0.09%
FCF per Share	-3.21	-0.86	-0.54	-0.42	-0.19	-0.52	-0.76	-0.46	-0.89	-0.86
FCF Conversion (FCF/Net Income)	0.79x	0.50x	0.61x	0.42x	0.28x	0.53x	0.62x	0.56x	0.74x	0.76x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-238.82%	-122.28%	-507.32%	-	-	-102.89%	-42.18%	-94.47%	-236.05%
Return on Invested Capital (ROIC)	-	-	-1807.35%	-1409.51%	-	-	-66.97%	-31.83%	-72.03%	-549.97%
Debt / Equity	-	-	-	-	-	-	0.03x	0.05x	-	-
Interest Coverage	-27.28x	-311.92x	-170.27x	-829.39x	-131.31x	-10.37x	-8.33x	-25.88x	-42.04x	-
FCF Conversion	0.79x	0.50x	0.61x	0.42x	0.28x	0.53x	0.62x	0.56x	0.74x	0.76x

Frequently Asked Questions

Growth & Financials

Protagenic Therapeutics, Inc. (PTIX) reported $-0.0M in revenue for fiscal year 2024. This represents a 100% decrease from $69.1M in 2009.

Protagenic Therapeutics, Inc. (PTIX) grew revenue by 0.0% over the past year. Growth has been modest.

Protagenic Therapeutics, Inc. (PTIX) reported a net loss of $8.9M for fiscal year 2024.

Dividend & Returns

Protagenic Therapeutics, Inc. (PTIX) has a return on equity (ROE) of -236.0%. Negative ROE indicates the company is unprofitable.

Protagenic Therapeutics, Inc. (PTIX) had negative free cash flow of $4.5M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Protagenic Therapeutics, Inc. (PTIX) 10-Year Financial Performance & Capital Metrics

PTIX • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersPsychiatric & CNS Disorders

Revenue $0
EBITDA -$6M -25.6%
Net Income -$6M -10.5%
EPS (Diluted) -1.13 +1.7%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -236.05% -149.9%
ROIC -549.97% -663.5%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Weak momentum: RS Rating 1 (bottom 1%)
✗Shares diluted 12.8% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-57.95%

EPS CAGR

10Y-

5Y-

3Y-

TTM23.58%

ROCE

10Y Avg-484.89%

5Y Avg-317.7%

3Y Avg-123.51%

Latest-243.57%

Peer Comparison

Psychiatric & CNS Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
ACADACADIA Pharmaceuticals Inc.	4.48B	26.46	19.46	31.85%	24.94%	28.47%	3.51%	0.07
JAZZJazz Pharmaceuticals plc	9.87B	162.43	18.78	6.12%	-8.86%	-9.31%	13.66%	1.51
CPRXCatalyst Pharmaceuticals, Inc.	2.75B	22.35	17.06	23.49%	37.63%	23.64%	8.71%	0.00
HRMYHarmony Biosciences Holdings, Inc.	2.06B	35.76	14.25	22.8%	22.48%	22.23%	10.62%	0.28
ALKSAlkermes plc	4.81B	29.15	13.43	-6.36%	22.27%	19.55%	8.43%	0.05
PRTCPureTech Health plc	437.45M	18.10	9.05	44.98%	-495.91%	-8.53%		0.05
LBRXLB Pharmaceuticals Inc Common Stock	500.67M	19.79	-1.11
NMRANeumora Therapeutics, Inc. Common Stock	363.67M	2.14	-1.40			-178.79%		0.01

Profit & Loss

	Jun 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	534	148	347	339	286	0	30	28.22K	50.29K
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	0	-534	-148	-347	-339	-286	0	-30	-28.22K	-50.29K
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	0.72%	-1.34%	0.02%	0.16%	1%	-	-939.6%	-0.78%
Operating Expenses+	491K	1.83M	2.37M	2.31M	2.09M	2.55M	4.14M	3.56M	4.5M	5.7M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	491K	1.3M	1.65M	1.43M	1.28M	1.85M	3M	1.97M	1.18M	1.76M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	464	417.87K	717.45K	881.19K	807.95K	699.8K	1.14M	1.59M	3.32M	3.85M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	404.17K	0	0	53	203	-1K	0	0	97K
Operating Income+	-491K	-2.23M	-2.37M	-2.31M	-2.09M	-2.55M	-4.14M	-3.56M	-4.53M	-5.7M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	0.5%	-3.55%	-0.06%	0.02%	0.1%	-0.22%	-0.62%	0.14%	-0.27%	-0.26%
EBITDA+	-490.86K	-2.23M	-2.36M	-2.31M	-2.09M	-2.55M	-4.14M	-3.56M	-4.5M	-5.65M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-0.41%	-3.55%	-0.06%	0.02%	0.1%	-0.22%	-0.62%	0.14%	-0.26%	-0.26%
D&A (Non-Cash Add-back)	143	534	148	347	339	286	286	30	28.22K	50.29K
EBIT	-1.02M	-2.27M	-2.37M	-2.31M	-2.09M	-2.55M	-4.14M	-3.42M	-4.53M	-5.53M
Net Interest Income+	0	-6.25K	0	0	-13.07K	-246K	-464K	48.33K	156.79K	43.46K
Interest Income	0	907	13.89K	2.79K	2.81K	502	33.21K	185.79K	264.48K	43.47K
Interest Expense	18K	7.16K	13.89K	2.79K	15.89K	246.18K	496.91K	137.46K	107.68K	0
Other Income/Expense	1.62K	-42.33K	105.69K	-243K	335.22K	2.88K	-383K	2.28K	-474K	175.61K
Pretax Income+	-1.02M	-2.28M	-2.26M	-2.56M	-1.75M	-2.55M	-4.52M	-3.56M	-5M	-5.53M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	-33K	0	0	0	15.89K	0	0	0	0	0
Effective Tax Rate %	0.47%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-476K	-2.28M	-2.26M	-2.56M	-1.75M	-2.55M	-4.52M	-3.56M	-5M	-5.53M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	0.56%	-3.78%	0.01%	-0.13%	0.32%	-0.46%	-0.77%	0.21%	-0.41%	-0.1%
Net Income (Continuing)	-1.02M	-2.28M	-2.26M	-2.56M	0	-2.55M	-4.52M	-3.56M	-5M	-5.53M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	-74K	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-73.23	-1.72	-0.88	-1.00	-0.69	-1.00	-1.24	-0.82	-1.15	-1.13
EPS Growth %	0.56%	0.98%	0.49%	-0.14%	0.31%	-0.45%	-0.24%	0.34%	-0.4%	0.02%
EPS (Basic)	-73.23	-1.72	-0.88	-1.00	-0.69	-1.00	-1.24	-0.82	-1.15	-1.13
Diluted Shares Outstanding	118.09K	1.33M	2.56M	2.56M	2.56M	2.58M	3.69M	4.32M	4.34M	4.9M
Basic Shares Outstanding	118K	1.33M	2.56M	2.56M	2.56M	2.58M	3.69M	4.32M	4.34M	4.9M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Jun 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	132K	3.16M	1.78M	696.27K	841.98K	879.25K	11.06M	8.04M	4.2M	1.88M
Cash & Short-Term Investments	62K	3.1M	1.69M	612.87K	798.62K	671.09K	10.37M	7.98M	4.06M	1.84M
Cash Only	62K	3.1M	399.69K	362.49K	798.62K	671.09K	541.17K	215.19K	1.29M	1.84M
Short-Term Investments	0	0	1.29M	250.39K	0	0	9.83M	7.76M	2.77M	0
Accounts Receivable	0	0	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	0	0	0	0	0
Total Non-Current Assets+	1K	1.1K	1.02K	611	296	0	0	1.77K	123.33K	73.05K
Property, Plant & Equipment	1K	1.1K	1.02K	611	296	0	0	1.77K	123.33K	73.05K
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	0	0	0	0	0	0	0
Total Assets+	133K	3.16M	1.78M	696.88K	842.27K	879.25K	11.06M	8.04M	4.32M	1.96M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	-0.46%	22.77%	-0.44%	-0.61%	0.21%	0.04%	11.58%	-0.27%	-0.46%	-0.55%
Total Current Liabilities+	189K	684.86K	561.69K	907.77K	1.2M	655.19K	799.53K	1.12M	655.25K	942.76K
Accounts Payable	168K	13.4K	10.96K	10.05K	163.03K	141.86K	278.96K	155.49K	113.8K	102.96K
Days Payables Outstanding	-	9.16K	27.04K	10.57K	175.53K	181.05K	-	1000K	1.47K	747.35
Short-Term Debt	0	0	0	0	0	0	0	344.23K	0	0
Deferred Revenue (Current)	-399	0	0	0	0	0	0	0	0	0
Other Current Liabilities	0	516.87K	425.84K	676.08K	332.22K	83.67K	0	0	0	0
Current Ratio	0.70x	4.62x	3.17x	0.77x	0.70x	1.34x	13.83x	7.18x	6.41x	2.00x
Quick Ratio	0.70x	4.62x	3.17x	0.77x	0.70x	1.34x	13.83x	7.18x	6.41x	2.00x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	515K	0	0	52.37K	279.37K	1.37M	318.43K	0	0	0
Long-Term Debt	515K	0	0	0	279.37K	1.37M	318.43K	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	0
Total Liabilities	704K	684.86K	561.69K	907.77K	1.48M	2.03M	1.12M	1.12M	655.25K	942.76K
Total Debt+	515K	0	0	0	279.37K	1.37M	318.43K	344.23K	0	0
Net Debt	453K	-3.1M	-399.69K	-362.49K	-519.25K	702.71K	-222.74K	129.04K	-1.29M	-1.84M
Debt / Equity	-	-	-	-	-	-	0.03x	0.05x	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-27.28x	-311.92x	-170.27x	-829.39x	-131.31x	-10.37x	-8.33x	-25.88x	-42.04x	-
Total Equity+	-571K	2.48M	1.22M	-210.88K	-634.37K	-1.15M	9.94M	6.92M	3.67M	1.01M
Equity Growth %	-7.16%	5.34%	-0.51%	-1.17%	-2.01%	-0.81%	9.65%	-0.3%	-0.47%	-0.72%
Book Value per Share	-4.84	1.87	0.48	-0.08	-0.25	-0.44	2.70	1.60	0.84	0.21
Total Shareholders' Equity	-497K	2.48M	1.22M	-210.88K	-634.37K	-1.15M	9.94M	6.92M	3.67M	1.01M
Common Stock	1	1.03K	1.03K	1.03K	1.03K	1.04K	1.72K	434	444	725
Retained Earnings	-1.55M	-8.58M	-10.84M	-13.4M	-15.15M	-17.7M	-22.22M	-25.78M	-30.78M	-36.3M
Treasury Stock	-100K	0	0	0	0	0	0	0	0	0
Accumulated OCI	-149	-181.63K	-167.81K	-170.54K	-172.36K	-171.59K	-248.35K	-676.91K	-113.55K	-129.85K
Minority Interest	-74K	0	0	0	0	0	0	0	0	0

Cash Flow

	Jun 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-378K	-1.14M	-1.38M	-1.07M	-487.99K	-1.35M	-2.8M	-1.99M	-3.7M	-4.22M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	0.52%	-2.02%	-0.21%	0.22%	0.54%	-1.76%	-1.07%	0.29%	-0.86%	-0.14%
Net Income	-476K	-2.28M	-2.26M	-2.56M	-1.75M	-2.55M	-4.52M	-3.56M	-5M	-5.53M
Depreciation & Amortization	1K	534	148	347	339	286	427.14K	30	28.22K	50.29K
Stock-Based Compensation	479	546.13K	888.28K	1.13M	797.76K	1.65M	1.52M	864.68K	666.83K	923.14K
Deferred Taxes	0	440.78K	-91.8K	0	-348.29K	-248.55K	-427.14K	0	0	0
Other Non-Cash Items	-7K	150K	99.78K	246.19K	110.91K	154.9K	345.95K	156.85K	716.09K	-132.14K
Working Capital Changes	104K	-1.94K	-16.87K	109.73K	702.2K	-361.43K	-140.39K	540.13K	-114.41K	467.54K
Change in Receivables	0	6	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	30K	52.25K	17.26K	98.59K	99.54K	0	340.12K	-91.6K	-27.33K	0
Cash from Investing+	-1K	0	-1.29M	1.05M	250K	0	-9.91M	1.6M	4.78M	2.8M
Capital Expenditures	-1K	0	0	0	0	0	0	-1.8K	-149.78K	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	-1.29K	1.05K	0	0	0	-46.05K	0	51.73K
Cash from Financing+	340K	4.28M	0	0	670K	1.22M	12.58M	0	0	1.96M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	4.26M	0	0	0	-104.09K	869.63K	0	0	-454
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-379K	-1.14M	-1.38M	-1.07M	-487.99K	-1.35M	-2.8M	-2M	-3.85M	-4.22M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	0.52%	-2.01%	-0.21%	0.22%	0.54%	-1.76%	-1.07%	0.29%	-0.93%	-0.09%
FCF per Share	-3.21	-0.86	-0.54	-0.42	-0.19	-0.52	-0.76	-0.46	-0.89	-0.86
FCF Conversion (FCF/Net Income)	0.79x	0.50x	0.61x	0.42x	0.28x	0.53x	0.62x	0.56x	0.74x	0.76x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-238.82%	-122.28%	-507.32%	-	-	-102.89%	-42.18%	-94.47%	-236.05%
Return on Invested Capital (ROIC)	-	-	-1807.35%	-1409.51%	-	-	-66.97%	-31.83%	-72.03%	-549.97%
Debt / Equity	-	-	-	-	-	-	0.03x	0.05x	-	-
Interest Coverage	-27.28x	-311.92x	-170.27x	-829.39x	-131.31x	-10.37x	-8.33x	-25.88x	-42.04x	-
FCF Conversion	0.79x	0.50x	0.61x	0.42x	0.28x	0.53x	0.62x	0.56x	0.74x	0.76x

Frequently Asked Questions

Growth & Financials

Protagenic Therapeutics, Inc. (PTIX) reported $-0.0M in revenue for fiscal year 2024. This represents a 100% decrease from $69.1M in 2009.

Protagenic Therapeutics, Inc. (PTIX) grew revenue by 0.0% over the past year. Growth has been modest.

Protagenic Therapeutics, Inc. (PTIX) reported a net loss of $8.9M for fiscal year 2024.

Dividend & Returns

Protagenic Therapeutics, Inc. (PTIX) has a return on equity (ROE) of -236.0%. Negative ROE indicates the company is unprofitable.

Protagenic Therapeutics, Inc. (PTIX) had negative free cash flow of $4.5M in fiscal year 2024, likely due to heavy capital investments.